CN104606229B - Blood product produces the method for freezing of employment raw blood plasma - Google Patents
Blood product produces the method for freezing of employment raw blood plasma Download PDFInfo
- Publication number
- CN104606229B CN104606229B CN201410850769.2A CN201410850769A CN104606229B CN 104606229 B CN104606229 B CN 104606229B CN 201410850769 A CN201410850769 A CN 201410850769A CN 104606229 B CN104606229 B CN 104606229B
- Authority
- CN
- China
- Prior art keywords
- blood plasma
- phase change
- cold accumulating
- change cold
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
The invention discloses the method for freezing that a kind of blood product produces employment raw blood plasma, this method includes：(1) cool down to phase change cold accumulating agent；(2) phase change cold accumulating agent to have cooled down and plasma bags are put into blood plasma frame, every bag of blood plasma is spaced, and interval places into the phase change cold accumulating agent；(3) the blood plasma frame is lain against in quick-freezer.Method provided by the invention can fast and effeciently frozen plasma.
Description
Technical field
The present invention relates to blood product production technical fields, and in particular, to blood product produces employment raw blood plasma
Method of freezing.
Background technology
Blood product belongs to biological products range, refers mainly to, using human normal plasma as raw material, using biological process or divide
The biologically active agents prepared from purification technique.After raw blood plasma acquisition freeze rapidly that wherein blood can be effectively ensured in a short time
The activity for starching albumen, the product purity that gained is prepared after isolating and purifying is high, and potency is high.《Pharmacopoeia of People's Republic of China》2010
Clear stipulaties in year version " after sampled plasma, should the quick freezing in 6 hours ".《Specification is advised in blood-collecting station quality management》9th
17 also clear stipulaties " necessary single part quick-frozen preservations in 6 hours of raw blood plasma after acquisition, forbid slurry ".
Platelet cofactor Ⅰ in fresh frozen plasma is unstable coagulation factor, and the half-life period in human body is 8~12
Hour, it inactivates within 30 minutes in 56 DEG C.The time of blood collection and the time of quick-frozen experience are to influence platelet cofactor Ⅰ activity
Principal element, the quick-frozen time is shorter, and the loss of platelet cofactor Ⅰ is fewer.This requires it is quick-frozen it is fast, quick-frozen effect is good
Method of freezing completes the quick-frozen of blood plasma.
Invention content
The present invention is directed to solve at least some of the technical problems in related technologies.For this purpose, the present invention
One purpose is to propose a kind of method for capableing of quick freezing people's raw blood plasma.
The present invention is the following discovery based on inventor and completes：
Ensure the activity of fresh frozen plasma and cryoprecipitate, it is necessary to cold chain and time are controlled in blood collection and supply
Chain, wherein plasma quick freezing technology are quality and the treatment that an important link, quick-frozen time and effect will be directly related to blood plasma
Effect.The method of freezing of the raw blood plasma of conventional is that packed blood plasma is directly placed into low temperature refrigerator or freezer, small by number
When after could fully charge, though meet specification, no matter in low temperature refrigerator or freezer transmitting medium is most of for air, connect
Limited area is touched, it is longer the time required to causing to freeze, it is unfavorable for ensureing the activity of active ingredient in blood plasma.Also a few methods are
Cooled down using plasma bags are dipped in liquid ethanol, but ethyl alcohol is volatile, smell is denseer, easily makes operating personnel uncomfortable, and ethyl alcohol
It is inflammable and explosive, there is security risk.
Inventor can be such that blood plasma quickly and effectively freezes it was unexpectedly observed that cooled down in advance using phase change cold accumulating agent and to it
Knot.As a result, in one aspect of the invention, the present invention provides the quick-frozen sides that a kind of blood product produces employment raw blood plasma
Method, technical scheme of the present invention can effectively make blood product produce employment raw blood plasma quick freezing.
According to an embodiment of the invention, this method includes：
(1) cool down to phase change cold accumulating agent；
(2) phase change cold accumulating agent to have cooled down and plasma bags staggered floor being put into blood plasma frame, every bag of blood plasma is spaced,
Interval places into the phase change cold accumulating agent；
(3) the blood plasma frame is lain against in quick-freezer.
Cold-storage material be it is a kind of by it is organic or (and) translucent (or opaque) for form of inorganic compound, sticky gluey mix
Object is closed, can absorb at low temperature and store a large amount of colds, and a large amount of colds can be released when temperature is higher, the long period keeps
The low temperature environment of itself and surrounding a small range.Wherein, phase change cold accumulating agent is applied relatively wide in building, food, medicine and other fields.
Phase change cold accumulating agent is grouped as by multigroup, generally includes main energy storage agent, phase transformation regulator, anti-cryogen, anti-phase separation agent, inducing agent excessively
Deng.Phase change cold accumulating agent used in the present invention is not particularly limited, but it is preferable to use phase change cold accumulating agent be：Transition temperature range-
30~-55 DEG C, cold storage capacity is big, and refrigerating effect is good, and health is nontoxic, cost-effective, can Reusability.
According to an embodiment of the invention, the present invention used in phase change cold accumulating agent latent heat it is big, degree of supercooling is small, conducts heat, preferably
Ground, latent heat of phase change are 320~370J/g, are capable of providing prolonged refrigeration effect in this way.
According to an embodiment of the invention, the main energy storage agent of the phase change cold accumulating agent used in the present invention is sodium chloride, safe and non-toxic,
It is non-corrosive, it is at low cost, it is easy to use.
According to an embodiment of the invention, carrying out cooling to phase change cold accumulating agent described in step (1) includes：The phase transformation is stored
Cryogen, which is put into -60~-80 DEG C of low temperature refrigerators, to cool down 10~20 hours.Thus, it is possible to increase between blood plasma and phase change cold accumulating agent
The temperature difference in heat transfer.
According to an embodiment of the invention, plasma bags described in step (2) can be single part plasma bags.
According to an embodiment of the invention, phase change cold accumulating agent described in step (2) and the plasma bags are in the blood plasma frame
Staggered floor is placed, and is in direct contact.Increase contact area in heat transfer as a result, changes the heat-conducting medium in heat transfer, blood plasma is made to freeze
Time greatly shorten, it is fast that blood plasma freezes molding, and the activity of wherein plasma protein can be effectively ensured.
Conventional raw blood plasma method of freezing is that packed blood plasma is directly placed into low temperature refrigerator or freezer, required when freezing
Between it is longer, a few methods are plasma bags to be dipped in liquid ethanol to cool down, but ethyl alcohol is volatile, inflammable and explosive, there is security risk.
Method provided by the invention using packed blood plasma is positioned in the phase change cold accumulating agent of cooling, change contact area in heat transfer,
Three temperature difference, heat-conducting medium factors so that heat transfer rate greatly increases, to achieve the purpose that be rapidly frozen blood plasma.Its
In, phase change cold accumulating agent cold storage capacity is big, and refrigerating effect is good, and health is nontoxic, cost-effective, can Reusability.By using the present invention
Method, blood plasma freezing speed can be made to greatly increase, the activity of wherein plasma protein is effectively ensured, be centrifuged rear gained
Cryoprecipitate potency is significantly raised, is also significantly increased by the human blood coagulation factors VIII yield of its preparation.
Description of the drawings
Fig. 1 shows according to one embodiment of present invention, the temperature trend map of blood plasma difference freezing method, wherein temperature
1 indicates that the blood plasma temperature for being put into -30 DEG C of phase change cold accumulating agents, temperature 2 indicate the blood plasma temperature for being not put into -30 DEG C of phase change cold accumulating agents
Degree；
Fig. 2 shows according to one embodiment of present invention, the temperature trend map of blood plasma difference freezing method, wherein temperature
1 indicates that the blood plasma temperature for being put into -55 DEG C of phase change cold accumulating agents, temperature 2 indicate the blood plasma temperature for being not put into -55 DEG C of phase change cold accumulating agents
Degree.
Specific implementation mode
The embodiment of the present invention is described below in detail, examples of the embodiments are shown in the accompanying drawings, wherein from beginning to end
Same or similar label indicates same or similar element or element with the same or similar functions.Below with reference to attached
The embodiment of figure description is exemplary, it is intended to for explaining the present invention, and is not considered as limiting the invention.
Phase change cold accumulating agent used purchase is in Beijing You Leng cold chains Science and Technology Ltd. in following embodiments, and blood plasma is by day of bestowing favour
Source Co., Ltd of blood-collecting station acquires.Single part plasma bags specification is 600ml.
Embodiment 1
1, -30 DEG C of phase change cold accumulating agents are put into cooling 10 hours in -60~-80 DEG C of low temperature refrigerators (Haier DW-86W42)；
2, -30 DEG C of phase change cold accumulating agents to have cooled down are taken out, one layer is placed in the bottom blood plasma frame (47cm*33cm*25cm)；
3, it is placed on single part plasma bags are smooth on -30 DEG C of phase change cold accumulating agents, every bag of blood plasma has certain intervals, cannot be overlapped
It stacks, interval places into phase change cold accumulating agent partition, then places -30 DEG C of phase change cold accumulating agents again in plasma bags, and so on,
Until piling.
4, blood plasma administrator dressed insulated cold wear, cap and gloves the blood plasma frame for putting blood plasma is lain against immediately it is quick-frozen cold
In library.
5, it is closely observed after being put into freezer, about 90 minutes or so whens observe that blood plasma fully charge is molded.
Embodiment 2
1, -30 DEG C of phase change cold accumulating agents are put into cooling 10 hours in -60~-80 DEG C of low temperature refrigerators (Haier DW-86W42)；
2, -30 DEG C of phase change cold accumulating agents to have cooled down are taken out, one layer is placed in blood plasma frame；
3, it is placed on single part plasma bags with temp probe are smooth on -30 DEG C of phase change cold accumulating agents, every bag of blood plasma has one
Fixed interval, cannot be overlapped stacking, and interval places into phase change cold accumulating agent partition, then places -30 DEG C of phase transformations again in plasma bags
Cold-storage material, and so on, until piling.
4, blood plasma administrator dressed insulated cold wear, cap and gloves the blood plasma frame for putting blood plasma is lain against immediately it is quick-frozen cold
In library, while one basket of number for being not put into -30 DEG C of phase change cold accumulating agents of placement is identical and carries single part blood plasma of temp probe
Bag starts quick-frozen, observation thermograph.
5, two kinds of freezing method temperature trend maps are as shown in Figure 1, wherein temperature 1 is to be put into the blood of -30 DEG C of phase change cold accumulating agents
Slurry temperature degree.It will be seen from figure 1 that 90 minutes whens, observe that the temperature for being put into -30 DEG C of phase change cold accumulating agents has reached -21 DEG C, and this
When the blood plasma temperature routinely freezed there was only -11 DEG C.
6, freeze situation into freezer observation blood plasma, be put into the frozen molding of blood plasma of -30 DEG C of phase change cold accumulating agents.
Embodiment 3
1, p- 40 DEG C of phase change cold accumulating agents cool down, and put it into -60~-80 DEG C of low temperature refrigerators (Haier DW-86W42)
Middle cooling 13 hours；
2, -40 DEG C of phase change cold accumulating agents to have cooled down are taken out, one layer is placed in blood plasma frame bottom；
3, it is placed on single part plasma bags are smooth on -40 DEG C of phase change cold accumulating agents, every bag of blood plasma has certain intervals, cannot be overlapped
It stacks, interval places into phase change cold accumulating agent partition, then places -40 DEG C of phase change cold accumulating agents again in plasma bags, and so on,
Until piling.
4, blood plasma administrator dressed insulated cold wear, cap and gloves the blood plasma frame for putting blood plasma is lain against immediately it is quick-frozen cold
In library.
5, it is closely observed after being put into freezer, rear blood plasma fully charge molding in about 85 minutes or so.
Embodiment 4
1, -50 DEG C of phase change cold accumulating agents are put into cooling 16 hours in -60~-80 DEG C of low temperature refrigerators (Haier DW-86W42)；
2, -50 DEG C of phase change cold accumulating agents to have cooled down are taken out, one layer is placed in blood plasma frame；
3, it is placed on single part plasma bags are smooth on -50 DEG C of phase change cold accumulating agents, every bag of blood plasma has certain intervals, cannot be overlapped
It stacks, interval places into phase change cold accumulating agent partition, then places -50 DEG C of phase change cold accumulating agents again in plasma bags, and so on,
Until piling.
4, blood plasma administrator dressed insulated cold wear, cap and gloves the blood plasma frame for putting blood plasma is lain against immediately it is quick-frozen cold
In library.
5, it is observed that being taken around 80 minutes or so to the molding of blood plasma fully charge from freezer is put into.
Embodiment 5
1, -55 DEG C of phase change cold accumulating agents are put into cooling 20 hours in -60~-80 DEG C of low temperature refrigerators (Haier DW-86W42)；
2, -55 DEG C of phase change cold accumulating agents to have cooled down are taken out, one layer is placed in blood plasma frame；
3, it is placed on single part plasma bags with temp probe are smooth on -55 DEG C of phase change cold accumulating agents, every bag of blood plasma has one
Fixed interval, cannot be overlapped stacking, and interval places into phase change cold accumulating agent partition, then places -55 DEG C of phase transformations again in plasma bags
Cold-storage material, and so on, until piling.
4, blood plasma administrator dressed insulated cold wear, cap and gloves the blood plasma frame for putting blood plasma is lain against immediately it is quick-frozen cold
In library, while one basket of number for being not put into -55 DEG C of phase change cold accumulating agents of placement is identical and carries single part blood plasma of temp probe
Bag starts quick-frozen, observation thermograph.
5, shown in two kinds of freezing method temperature trend Fig. 2, wherein temperature 1 is to be put into the blood plasma temperature of -55 DEG C of phase change cold accumulating agents
Degree.Figure it is seen that 76 minutes whens, observe that the blood plasma temperature for being put into -55 DEG C of phase change cold accumulating agents has reached -27 DEG C, and this
When the blood plasma that routinely freezes there was only -10 DEG C.
6, blood plasma, frozen molding are observed into freezer.
Embodiment 6
1, -50 DEG C of phase change cold accumulating agents are put into cooling 16 hours in -60~-80 DEG C of low temperature refrigerators (Haier DW-86W42)；
2, -50 DEG C of phase change cold accumulating agents to have cooled down are taken out, one layer is placed in blood plasma frame；
3, per the single part blood plasma of 600ml two parts will be equally divided into when adopting slurry, -50 DEG C of phase change cold accumulating agents of a use, separately
A conventional placement, then put it into quick-freezer；
4, after 12 hours, blood plasma, frozen molding are observed into freezer.Take out frozen blood plasma detection platelet cofactor Ⅰ
Potency.Titration method reference《Chinese Pharmacopoeia》Human blood coagulation factors VIII Determination method (a phase method) in version annex in 2010,
According to GB18469-2001 Whole Blood ＆ Blood Components quality requirements, finished product cryoprecipitate prepared by every bag of 200ml fresh frozen plasma is solidifying
VIII contents of F >=80IU in blood factor must not be less than 0.4IU/ml.
5, the blood plasma bioactivity result that above two is freezed through different modes is as follows：
| Sample | - 50 DEG C of phase change cold accumulating agent frozen plasmas | Conventional frozen plasma |
| Potency | 0.62IU/ml | 0.43IU/ml |
6, by comparing result it is found that being apparently higher than routine using platelet cofactor Ⅰ potency in the quick-frozen blood plasma of phase change cold accumulating agent
The activity of platelet cofactor Ⅰ in blood plasma has been effectively ensured in method.
Embodiment 7
1, -55 DEG C of phase change cold accumulating agents are put into cooling 20 hours in -60~-80 DEG C of low temperature refrigerators (Haier DW-86W42)；
2, -55 DEG C of phase change cold accumulating agents to have cooled down are taken out, one layer is placed in blood plasma frame；
3, it is placed on single part plasma bags are smooth on -55 DEG C of phase change cold accumulating agents, every bag of blood plasma has certain intervals, cannot be overlapped
It stacks, interval places into phase change cold accumulating agent partition, then places -55 DEG C of phase change cold accumulating agents again in plasma bags, and so on,
Until piling.
4, blood plasma administrator dressed insulated cold wear, cap and gloves the blood plasma frame for putting blood plasma is lain against immediately it is quick-frozen cold
In library.
5, it is observed that being taken around 80 minutes or so to the molding of blood plasma fully charge from freezer is put into.
Embodiment 8
1, molding blood plasma will be freezed in embodiment 6 and carry out outbound screening, removing has piarhemia, haemolysis, has grumeleuse, fiber egg
The blood plasma of white precipitation and plasma bags breakage, then carry out the production of cryoprecipitate.
2, the blood plasma after verification screening places them in 2-15 DEG C of freezer and melts overnight, before blood plasma broken bag merges
It is impregnated 2-5 minutes in the alcohol of 75% concentration, taking-up is fully eluted with cold water for injection, then broken bag puts into collecting tank.
3, using GQ-142 type centrifuges (producer：Shanghai centrifugal machine research institute) it is centrifuged, centrifugation starts first 30 points
Clock opens -20 DEG C of refrigerants of centrifuge, and the intracavitary of centrifuge is allowed to reach the state of cooling.
4, it is centrifuged 1~3 hour with the speed of 10000~16000rpm under the conditions of 0-4 DEG C.
5, after centrifuging, cryoprecipitate is taken out, sampling is put into preprepared sample cell (10ml), and detect effect
Valence, the potency that gained cryoprecipitate is centrifuged with conventional method frozen plasma compare.Titration method reference《Chinese Pharmacopoeia》
Human blood coagulation factors VIII Determination method (a phase method) in version annex in 2010.
6, comparing result such as following table：
7, by comparing result it is found that obviously high using the quick-frozen blood plasma centrifugation gained cryoprecipitate potency of phase change cold accumulating agent
In conventional method, the activity of platelet cofactor Ⅰ in blood plasma has been effectively ensured.
Embodiment 9
1, the blood plasma for using phase change cold accumulating agent quick-frozen in embodiment 5 is centrifuged into the cold of gained with the blood plasma routinely freezed
With water for injection, (cryoprecipitate and the volume ratio of water for injection are precipitation (it is identical to produce the method for cryoprecipitate with embodiment 8) respectively
1:5~1:10) it dissolves；
2, using GQ-142 type centrifuges (producer：Shanghai centrifugal machine research institute) with the speed of 10000~16000rpm
Centrifugation is carried out 1~3 hour to acquired solution；
3, supernatant is taken, according to《Blood product removal/inactivation of viruses technical method and verification guide principle》, carry out S/D
Inactivation of virus, inactivator are 1% polyoxyethylene sorbitan monoleate, and 0.3% tributyl phosphate is added to after centrifuged supernatant and is handled extremely at 24 DEG C
It is 8 hours few；
4, the liquid after inactivation of virus is isolated and purified through Ago-Gel prepares human blood coagulation factors VIII refined liquid.It loading and washes
Wash, elution flow rate be 1.0~3.0L/ minute, it is washed to afford human blood coagulation factors VIII refined liquid, according to refined liquid potency use
Dilution (such as sodium citrate, lysine etc.) is diluted to the stoste that potency is 20~30IU/ml, with every bottle after aseptic filtration
10ml is filling, half tamponade, and filling half tamponade product is transferred quickly in body of freeze dryer, is freeze-dried, and it is solidifying that people is made
VIII finished product of blood factor, specification are 200IU/ bottles；
5, yield (the total bottle number of yield=human blood coagulation factors VIII finished product/blood plasma used weight) is calculated separately by formula, with
For 200IU/ bottles, human blood coagulation factors VIII finished product 0.35 can be made in the blood plasma routinely freezed per 1kg under same production technology
Bottle, and 0.41 bottle of human blood coagulation factors VIII finished product can be made in the blood plasma for using phase change cold accumulating agent quick-frozen under same production technology.
4, by result above it is found that using the quick-frozen blood plasma of phase change cold accumulating agent because from collect freeze used in the time it is short,
Effective protection wherein platelet cofactor Ⅰ activity, gained cryoprecipitate potency is high, therefore significantly improves human blood coagulation factors VIII product
Yield.
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means specific features, structure, material or spy described in conjunction with this embodiment or example
Point is included at least one embodiment or example of the invention.In the present specification, schematic expression of the above terms are not
It must be directed to identical embodiment or example.Moreover, particular features, structures, materials, or characteristics described can be in office
It can be combined in any suitable manner in one or more embodiments or example.In addition, without conflicting with each other, the skill of this field
Art personnel can tie the feature of different embodiments or examples described in this specification and different embodiments or examples
It closes and combines.
Although the embodiments of the present invention has been shown and described above, it is to be understood that above-described embodiment is example
Property, it is not considered as limiting the invention, those skilled in the art within the scope of the invention can be to above-mentioned
Embodiment is changed, changes, replacing and modification.
Claims (5)
1. a kind of method of freezing of blood product production employment raw blood plasma, which is characterized in that including：
(1) phase change cold accumulating agent is put into -60~-80 DEG C of low temperature refrigerators and is cooled down 10~20 hours；
(2) phase change cold accumulating agent to have cooled down and plasma bags are put into blood plasma frame, every bag of blood plasma is spaced, and interval is again
It is put into the phase change cold accumulating agent；
(3) the blood plasma frame is lain against in quick-freezer,
Wherein, the transition temperature range of the phase change cold accumulating agent is -30~-55 DEG C,
The latent heat of phase change of the phase change cold accumulating agent is 320~370J/g.
2. according to the method described in claim 1, it is characterized in that, the main energy storage agent of the phase change cold accumulating agent is sodium chloride.
3. according to the method described in claim 1, it is characterized in that, plasma bags described in step (2) are single part plasma bags.
4. according to the method described in claim 1, it is characterized in that, phase change cold accumulating agent described in step (2) and plasma bags are in institute
Staggered floor in blood plasma frame is stated to place.
5. according to the method described in claim 1, it is characterized in that, plasma bags described in step (2) and the phase change cold accumulating agent
It is in direct contact in the blood plasma frame.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410850769.2A CN104606229B (en) | 2014-12-30 | 2014-12-30 | Blood product produces the method for freezing of employment raw blood plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410850769.2A CN104606229B (en) | 2014-12-30 | 2014-12-30 | Blood product produces the method for freezing of employment raw blood plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104606229A CN104606229A (en) | 2015-05-13 |
| CN104606229B true CN104606229B (en) | 2018-10-09 |
Family
ID=53141049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410850769.2A Active CN104606229B (en) | 2014-12-30 | 2014-12-30 | Blood product produces the method for freezing of employment raw blood plasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104606229B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109865165A (en) * | 2019-04-02 | 2019-06-11 | 西安市中心血站（陕西省血液中心） | A kind of component blood preparation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679627A (en) * | 2005-01-12 | 2005-10-12 | 马建川 | Universal fresh frozen blood plasma |
| CN102533224A (en) * | 2010-12-28 | 2012-07-04 | 中国科学院广州能源研究所 | Low temperature phase change coolant |
| US20120197810A1 (en) * | 2011-01-28 | 2012-08-02 | Haarmann Klaus H | Selecting Packaging and Coolant Systems for Shipment of Biological Products |
-
2014
- 2014-12-30 CN CN201410850769.2A patent/CN104606229B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679627A (en) * | 2005-01-12 | 2005-10-12 | 马建川 | Universal fresh frozen blood plasma |
| CN102533224A (en) * | 2010-12-28 | 2012-07-04 | 中国科学院广州能源研究所 | Low temperature phase change coolant |
| US20120197810A1 (en) * | 2011-01-28 | 2012-08-02 | Haarmann Klaus H | Selecting Packaging and Coolant Systems for Shipment of Biological Products |
Non-Patent Citations (1)
| Title |
|---|
| "PHASE CHANGE MATERIALS (PCM) FOR THERMAL CONTROL DURING SPACECRAFT TRANSPORTATION";ARUN KUMAR.S，等;《International Journal of Mechanical and Industrial Engineering》;20131231;第3卷;第28-32页。 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104606229A (en) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105123671B (en) | A kind of cells frozen storing liquid, using and immunocyte cryopreservation methods | |
| CN104906052B (en) | A kind of preparation method of autologous platelet rich plasma freeze-dried powder | |
| Moroff et al. | Concepts about current conditions for the preparation and storage of platelets | |
| CN106332869B (en) | Fat mesenchymal stem cell frozen stock solution and fat mesenchymal stem cell cryopreservation methods | |
| US20070166389A1 (en) | Stabilized lyophilized blood platelets | |
| Shuja et al. | Development and testing of low-volume hyperoncotic, hyperosmotic spray-dried plasma for the treatment of trauma-associated coagulopathy | |
| US20180334655A1 (en) | Biologic composition and method of manufacture | |
| CN112229148A (en) | Vacuum freeze-drying method for pseudo-ginseng and application thereof | |
| Slichter et al. | Platelets stored in whole blood at 4° C: in vivo posttransfusion platelet recoveries and survivals and in vitro hemostatic function | |
| JPH04503666A (en) | Red blood cell freezing method | |
| CN103405754B (en) | Solubilization technology for producing human fibrinogen | |
| CN110193025B (en) | Exosome freeze-dried powder derived from human adipose-derived stem cells, and preparation method and application thereof | |
| CN103548814A (en) | Non-programmable-controlled cooling cryopreservation method and protection agent for hematopoietic stem cells at minus 80DEG C | |
| Prentice | Acquired coagulation disorders | |
| CN111592591B (en) | Preparation method of human von willebrand factor/human blood coagulation factor VIII compound, product and application | |
| CN104606229B (en) | Blood product produces the method for freezing of employment raw blood plasma | |
| CN103907595A (en) | Trehalose-containing blood platelet low-temperature preserving fluid and application thereof | |
| Kasper et al. | Determinants of factor VIII recovery in cryoprecipitate | |
| CN108976297A (en) | A kind of preparation method of cryoprecipitate and its application in human blood coagulation factors VIII production | |
| CN111587877A (en) | Stem cell cryopreservation protective agent, preparation method and application | |
| Strumia et al. | The development of plasma preparations for transfusions | |
| CN203550481U (en) | System for maintaining stable pressure difference of both ends of tunnel oven | |
| CN109593747A (en) | A kind of method of Human Factor Ⅸ Complex's intermediate products liquid storage | |
| CN101190234A (en) | Virus deactivation bagged freeze-dried plasma and uses thereof | |
| CN110604745B (en) | Method for producing platelet dry powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |